Jak Inhibitor Ruxolitinib Comfort-Ii Trial Shows Positive Results

JAK Inhibitor Ruxolitinib COMFORT-II Trial Shows Positive Results

Current research into JAK inhibitors - specifially ruxolitinib, pacritinib, and momelotinib

VJHemOnc – Video Journal of Hematology & HemOnc

The COMFORT-I and COMFORT-II Trials in Myelofibrosis

Targeted Oncology

Dr. Ruben Mesa Discusses the COMFORT Ruxolitinib Trials

COMFORT-II clinical trial: the 5 yr results

VJHemOnc – Video Journal of Hematology & HemOnc

Update on JAK Inhibitor — COMFORT II Trial interview with Claire Harrison, MD, at ASH 2011

How to Manage Side Effects of JAK Inhibitors for Mylofibrosis in the Clinical Practice

RESPONSE-2: 5-year follow-up of second-line ruxolitinib therapy for PV

VJHemOnc – Video Journal of Hematology & HemOnc

Update on JAK Inhibitors for Myelofibrosis: There is more than one

Analyses from COMFORT trials of ruxolitinib for myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Safety of treating myelofibrosis with ruxolitinib – results from JUMP trial

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Oh Discusses the Differences Between Investigational JAK Inhibitors and Ruxolitinib in MPNs

JAK inhibition for the early treatment of myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Evidence Supports Rechallenging of JAK Inhibitors in Myelofibrosis

Targeted Oncology

What Effects Has Jakafi® (ruxolitinib) Shown in Clinical Trials?

JAKAFI ruxolitinib

My view on current and future use of JAK inhibitors for ET, PV, and MF

The 5-year update on the COMFORT-II clinical trial of ruxolitinib

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Mesa Discusses JAK Inhibitors for Myelofibrosis

Phase 3 Trial of Momelotinib Versus Ruxolitinib in JAK Inhibitor Naive Patients with Myelofibrosis

Combination Therapy with JAK2 inhibitors in MPN